Adicet Bio Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(a)None.
(b) On December 13, 2024, Francesco Galimi, our former Chief Medical Officer, terminated a trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Dr. Galimi’s Rule 10b5-1 trading plan, adopted on November 1, 2024, provided for the sale from time to time of a maximum of 400,000 shares of our common stock pursuant to the terms of the plan. If Dr. Galimi’s Rule 10b5-1 trading plan had not been terminated, it would have expired on November 3, 2025, or earlier if all transactions under the trading arrangement were completed. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.